Lux Capital

Lux Capital
Private
Industry Venture capital
Founded 2000
Founders Peter Hébert
Robert Paull
Josh Wolfe
Headquarters New York, NY, USA
Website luxcapital.com

Lux Capital is a venture capital firm founded by Peter Hébert, Robert Paull, and Josh Wolfe[1] in 2000[2] . The firm, based in New York with an office in Menlo Park, invests in emerging technologies in the physical and life sciences.[3][4] The Lux Capital team has built more than 20 companies from scratch.[3]

Lux Capital's portfolio companies include Accelergy, Cambrios, Cerulean Pharma, Crystal IS, Everspin, Evolv Technologies, Genocea Biosciences, Gridco Systems, Kala Pharmaceuticals, Magen Biosciences, Molecular Imprints, Nanosys, Visterra, QD Soleil, SiBEAM, Shapeways, Silicon Clocks, Siluria Technologies, Sols and Transphorm.[5]

In April 2011, former McKinsey Senior Partner Richard N. Foster and former CIA Director James Woolsey joined Lux Capital as venture partners.[6] In August 2012, form Pfizer Chairman and CEO Jeff Kindler joined Lux Capital as a venture partner.[7]

Lux manages about $350 million in assets.[8]

See also

References

  1. ↑ Fickenscher, Lisa (2003). "2003 40 Under 40". Crain's New York Business. Jan 27 - Feb 2, 2003: 15–31. ISSN 8756-789X. OCLC 11620213.
  2. ↑ Eden, Scott (2009). "Nano Wunderkinds". Dealmaker. December/January 2009: 35–37. ISSN 1937-304X. OCLC 132936538.
  3. ↑ 3.0 3.1 Bigelow, Bruce V. (6 May 2009). "Lux Capital’s Larry Bock and Josh Wolfe Warm to Venture Deals Despite Nuclear Winter". Xconomy. Retrieved 17 January 2010.
  4. ↑ Timmerman, Luke (23 Dec 2009). "Kala Pharmaceuticals, Stealthy New Company Tied to MIT’s Bob Langer, Gets $2M". Xconomy. Retrieved 18 January 2010.
  5. ↑ "All Investments made by Lux Capital". Crunchbase. 10 Dec 2014. Retrieved 10 December 2014.
  6. ↑ "James Woolsey and Richard Foster Join Lux Capital as Venture Partners". Business Wire. 26 April 2011.
  7. ↑ "Kindler, Former Pfizer Chief, Joins Lux Capital". Dealbook. 8 August 2012.
  8. ↑ "Lux Capital Raises $245 Million to Fund Unpopular Science Startups". Bloomberg. 13 February 2013.

External links